PHASE I STUDY OF ORAL CEP-701 IN PATIENTS WITH SOLID TUMORS

$0M01FY2000RRNIH

University Of Chicago, Chicago IL

Investigators

Linked publications & trials

Paper 33788946 Paper 32889963 Paper 30535721 Paper 27459230 Paper 27210268 Paper 25885822 Paper 25840648 Paper 25544740 Paper 25411163 Paper 24882155 Paper 24823702 Paper 24732925 Paper 24588711 Paper 24285773 Paper 23986859 Paper 23913942 Paper 23806029 Paper 23633200 Paper 23576237 Paper 23553855 Paper 23447518 Paper 23308388 Paper 22986150 Paper 22867037 Paper 22847947 Paper 22763622 Paper 22763267 Paper 22544009 Paper 22541936 Paper 22101912 Paper 21798578 Paper 21671531 Paper 21632481 Paper 21530736 Paper 21426455 Paper 21112019 Paper 21050867 Paper 20816944 Paper 20798258 Paper 20624651 Paper 20553679 Paper 20414144 Paper 20332249 Paper 20176450 Paper 20150301 Paper 20100807 Paper 20091113 Paper 20070572 Paper 19968402 Paper 19955752 Paper 19910025 Paper 19837518 Paper 19782423 Paper 19773379 Paper 19756530 Paper 19657584 Paper 19646680 Paper 19595703 Paper 19567526 Paper 19444258 Paper 19302083 Paper 19255602 Paper 19240158 Paper 19240152 Paper 19133287 Paper 19124843 Paper 19056602 Paper 19026577 Paper 18936915 Paper 18925859 Paper 18839415 Paper 18770076 Paper 18719052 Paper 18702049 Paper 18655531 Paper 18650797 Paper 18647805 Paper 18622306 Paper 18606653 Paper 18591489 Paper 18581219 Paper 18577985 Paper 18521921 Paper 18516218 Paper 18403759 Paper 18346991 Paper 18245794 Paper 18179313 Paper 18172212 Paper 18158263 Paper 17961988 Paper 17932107 Paper 17901983 Paper 17560739 Paper 17552955 Paper 17520786 Paper 17477941 Paper 17442599 Paper 17308390 Paper 17264335

Abstract

This Phase I, two-institution study will investigate CEP-701, an oral tyrosine kinase inhibitor. The purpose of this study is to determine the maximum tolerated dose of CEP-701 administered twice daily for twenty-eight days in patients with advanced solid tumors. This study will also identify the toxicities of CEP-701.

View original record on NIH RePORTER →